Study of E7389 Liposomal Formulation in Participants With Solid Tumor
NCT03207672
·
clinicaltrials.gov ↗
PHASE1
Phase
ACTIVE_NOT_RECRUITING
Status
140
Enrollment
INDUSTRY
Sponsor class
Conditions
Solid Tumor
Interventions
DRUG:
E7389-LF
Sponsor
Eisai Co., Ltd.